Chinese eye disease specialist Elumninex Biosciences has raised a $50 million Series A round led by GL Ventures, Lilly Asia Ventures (LAV), and Quan Capital.
Antengene, a China-based drug developer that previously raised $238 million across three private funding rounds, closed roughly flat on its first day of trading in Hong Kong following a HK$2.78 billion ($359 million) IPO.
D3 Bio, a Chinese drug developer that studies and specifically targets areas where existing approaches to care are not delivering satisfactory outcomes, has raised $200 million in Series A funding.
KKR has acquired Argenta, a New Zealand-based animal health services provider, for an undisclosed sum.
Goldman Sachs has invested INR11.2 billion ($150 million) in Biocon Biologics, the biosimilars business of Indian pharmaceuticals manufacturer Biocon, at a post-money valuation of $3.94 billion.
RA Capital and Hillhouse Capital have led a $120 million Series D round for Cytek Biosciences, a California-based cell analysis start-up founded by a former professor at Shanghai's Fudan University.
Duncan Zheng, head of China private equity at Investcorp, observes that COVID-19 dislocation has created some timely inroads as the firm’s broader expansion agenda ramps up
JW Therapeutics, a private equity-backed Chinese drug developer specializing in CAR T-cell therapies that engineer immune cells to fight cancers, has raised HK$2.33 billion ($300 million) through a Hong Kong IPO.
Chinese biotech player CARsgen Therapeutics has raised $186 million in Series C funding led by Loyal Valley Capital.
Eight Roads Ventures has recruited Xin Liu, formerly of Greater Pacific Capital, as a partner in its China team.
Genecast Biotechnology, a Chinese gene sequencing and precision diagnostics company, has closed a RMB1 billion ($149 million) Series E funding round led by China Structural Reform Fund.
LianBio, a Chinese biotech start-up incubated earlier this year by life sciences investor Perceptive Advisors, has raised $310 million from a group featuring BlackRock.
Wellington Management, OrbiMed and Morningside Ventures have led a $100 million Series C round for Gracell Biotechnologies, a China-based developer of cancer treatments.
New Zealand infrastructure investors Infratil and HRL Morrison have offered to acquire a 75% stake in Australia-based radiology business Qscan for an enterprise valuation of A$735 million ($524 million), facilitating an exit for Quadrant Private Equity.
Chinese online-to-offline (O2O) medicine retailer Dingdang Kuaiyao has raised RMB1 billion ($150 million) in an extended Series B round featuring Dragon Gate Investment Partners.
3D Diagnostic, a diagnostics spinout from Chinese tumor immunotherapy specialist 3D Medicines, has raised RMB1.5 billion ($224 million) in funding led by CPE, formerly known as CITIC Private Equity.
Swedish private equity firm Summa Equity has acquired a controlling stake in Singapore-based biotech developer Sengenics for an undisclosed sum, setting up an exit for Japan’s SBI Holdings.
China’s 3H Health Investment has led a RMB450 million ($67 million) Series B round for local genetics-based drug discovery and therapeutics developer EdiGene.
BGH Capital and Ontario Teachers’ Pension Plan (OTPP) have improved their take-private offer for New Zealand dentistry chain Abano, reflecting a relatively strong business recovery.
PAG Asia Capital has made its second substantial investment in India in the past two months, leading a consortium that has agreed to acquire a controlling stake in Anjan Drug, a Chennai-based manufacturer of active pharmaceutical ingredients (API).
Hong Kong-based Zhaoke Ophthalmology Pharmaceutical (ZKO), a subsidiary of Lee’s Pharmaceutical, has raised a $145 million Series B round led by Hillhouse Capital and TPG Asia.
Tatsuo Kawasaki, a partner at Unison Capital, on supporting existing investments and making new ones, expectations of distress in Japan, and why a platform approach makes sense for healthcare
Everest Medicines, a Chinese biotech start-up backed by CBC Group, performed strongly in early trading in Hong Kong following a HK$3.5 billion ($451 million) IPO.
China-based Genor Biopharma, which counts Hillhouse Capital, Temasek Holdings and Qiming Venture Partners among its investors, has raised HK$2.88 billion ($372 million) through a Hong Kong IPO.